EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Edaravone is a Therapeutic Candidate for Doxorubicin‐Induced Cardiomyopathy by Activating the Nrf2 Pathway

Naoki Yoshikawa iD, Naoto Hirata, Yuichiro Kurone, Sadahiko Shimoeda

Pharmacology Research & Perspectives · 2025-02 · 13 (1)

DOI: 10.1002/prp2.70066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 25.01.2025. Verfasst von Naoki Yoshikawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Health Care and Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. Hauptthemen laut MEDLINE: Edaravone, Doxorubicin, NF-E2-Related Factor 2, Cardiomyopathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (DOXO) has long been used clinically and remains a key drug in cancer therapy. DOXO‐induced cardiomyopathy (DICM) is a chronic and fatal complication that severely limits the use of DOXO. However, there are very few therapeutic agents for DICM, and there is an urgent need to identify those that can be used for a larger number of patients. The most likely pathogenic mechanism of DICM is the involvement of reactive oxygen species (ROS) and promotion of cell death. In this study, we investigated the efficacy and mechanism of action of edaravone (EDA), a known radical scavenger in DICM. Two methods of EDA administration were employed: daily and weekly. Our results showed that the daily administration group had prolonged survival periods and preserved the left ventricular ejection fraction in DICM mice. In contrast, in the weekly treatment group, slight improvements were observed in these indicators compared with those in DICM mice; however, none of them were statistically significant. These results show that the daily administration group had a higher efficacy than the weekly administration group. Gene‐expression results showed that Nrf2 and its related genes were upregulated in the daily group but not in the weekly group. Based on these results, we hypothesized that the Sirt1/Nrf2/HO‐1 and ABCB4 pathways were involved in EDA. However, there is limited evidence that EDA is effective against DICM. The findings obtained herein bolster the evidence in DICM by demonstrating prolonged survival and continued preservation of cardiac function and proposing a possible mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EdaravoneDoxorubicinNF-E2-Related Factor 2CardiomyopathiesFree Radical ScavengersAnimalsMiceMaleSignal TransductionReactive Oxygen SpeciesDisease Models, AnimalSirtuin 1Antibiotics, AntineoplasticMice, Inbred C57BLVentricular Function, Left

Stichwörter der Autor:innen

Nrf2anthracyclinedexrazoxanedoxorubicindoxorubicin‐induced cardiomyopathyedaravone

Substanzen

EdaravoneDoxorubicinNF-E2-Related Factor 2Nfe2l2 protein, mouseFree Radical ScavengersReactive Oxygen SpeciesSirtuin 1Antibiotics, AntineoplasticSirt1 protein, mouse

Autor:innen und Institutionen

  • Department of Pharmaceutical Health Care and Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.

ORCID-Profile: Naoki Yoshikawa

Zitieren

APA

Yoshikawa, N., Hirata, N., Kurone, Y., & Shimoeda, S. (2025). Edaravone is a Therapeutic Candidate for Doxorubicin‐Induced Cardiomyopathy by Activating the Nrf2 Pathway. Pharmacology Research & Perspectives, 13(1). https://doi.org/10.1002/prp2.70066

Vancouver

Yoshikawa N, Hirata N, Kurone Y, Shimoeda S. Edaravone is a Therapeutic Candidate for Doxorubicin‐Induced Cardiomyopathy by Activating the Nrf2 Pathway. Pharmacology Research & Perspectives. 2025;13(1). doi:10.1002/prp2.70066

BibTeX
@article{Yoshikawa2025,
  author = {Yoshikawa, Naoki and Hirata, Naoto and Kurone, Yuichiro and Shimoeda, Sadahiko},
  title = {Edaravone is a Therapeutic Candidate for Doxorubicin‐Induced Cardiomyopathy by Activating the Nrf2 Pathway},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  volume = {13},
  number = {1},
  doi = {10.1002/prp2.70066}
}
Kostenlos starten →